Iterum Therapeutics Q4 net loss $6.6M; cash $24.1M, ORLYNVAH approved

Iterum Therapeutics plc

2024-FY EPS reported -$1.26

Net loss Q4 2024 $6.6M vs $12.4M in Q4 2023; full year $24.8M vs $38.4M.
Cash and equivalents $24.1M at Dec 31, 2024; including $4.8M ATM proceeds Jan-Feb 2025, runway into H2 2025.
R&D expenses fell to $1.3M in Q4 2024 from $9.7M, driven by lower REASSURE trial costs.
ORLYNVAH (sulopenem etzadroxil/probenecid) approved by FDA for uUTIs in Q4 2024; pre-commercialization underway.
Repaid outstanding 6.500% Exchangeable Notes due 2025 in January 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.